The EPS beat provides short-term relief, but the underlying organic revenue decline and reiterated guidance (flat growth, $1.85-$2.05 EPS) cap upside. Watch for resolution of the Novum IQ pump hold and tariff impact in Q2 commentary. The stock may trade range-bound until organic growth inflects positively.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 30 $17.58entry
- T+1 · 7mo ago −2.10%α −2.32% · $17.21
- T+5 · 6mo ago −3.41%α −5.14% · $16.98
- T+20 · 6mo ago +9.50%α +4.53% · $19.25
- T+60 · 4mo ago +32.76%α +29.66% · $23.34
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Baxter reported Q1 2026 adjusted diluted EPS of $0.36, beating the $0.31 consensus by 16.1%, on revenue of $2.70B vs. $2.62B consensus (+3.1% beat). However, organic sales declined 1% YoY, adjusted EPS fell 35% YoY, and the company merely reiterated its full-year 2026 outlook of flat organic growth and adjusted EPS of $1.85-$2.05. The combination of a headline beat with deteriorating underlying trends (declining organic revenue, tariff headwinds, ongoing Novum IQ pump hold) makes this a mixed filing.
Key Financial Metrics
Key Facts
- Q1 2026 adjusted diluted EPS from continuing operations was $0.36, beating consensus of $0.31 by 16.1%
- Q1 2026 revenue was $2.701B, beating consensus of $2.62B by 3.1%
- Organic sales declined 1% YoY; U.S. organic sales fell 4%
- Adjusted diluted EPS from continuing operations declined 35% YoY from $0.55
- Full-year 2026 outlook reiterated: organic sales growth approximately flat, adjusted EPS $1.85-$2.05
- GAAP diluted EPS from continuing operations was ($0.03), vs $0.13 in Q1 2025
- Free cash flow from continuing operations was $76M, improving from ($221M) in Q1 2025
- Quarterly dividend declared at $0.01 per share, unchanged
- Novum IQ LVP shipment and installation hold continues to weigh on Infusion Therapies sales
- Tariff costs and higher manufacturing costs impacted results in the quarter
Financial Impact
Adjusted EPS beat consensus by $0.05 (16.1%), but organic revenue declined 1% YoY and adjusted EPS fell 35% YoY
Risk Factors
- Novum IQ LVP shipment hold continues to pressure Infusion Therapies sales
- Tariff costs and higher manufacturing costs are compressing margins
- U.S. organic sales declined 4% YoY, signaling weak domestic demand
- Adjusted EPS guidance of $1.85-$2.05 implies no acceleration from Q1 run-rate
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-028582 |
| Document: bax-20260429.htm | 0001628280-26-028582 |
| Document: 0001628280-26-028582-index-headers.html | 0001628280-26-028582 |
| Document: 0001628280-26-028582-index.html | 0001628280-26-028582 |
| Document: 0001628280-26-028582.txt | 0001628280-26-028582 |
| 8-K Data (Synthetic) | 0001628280-26-028582 |
Track record
15 reports on BAX
3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +9.15% at T+5 after the Oct 29, 2026 report. 4 of 5 went positive at some point.
Filters
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $23.50 to $25.65 Now $25.54 +8.68% ▲ +9.15% +13.87% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $24.92 to $25.49 Now $25.54 +2.49% ▲ +2.29% +4.28% vs SPY
- Oct 23, 202624d ago Institutional Cluster Neutral 2/10 Entry $25.30 to $23.00 Now $25.54 +0.95% ▼ −9.09% −8.53% vs SPY
- Aug 19, 202612w ago 8-K Neutral 3/10 Entry $26.64 to $26.50 Now $25.54 −4.13% ▼ −0.53% −0.14% vs SPY
- Aug 18, 202612w ago 8-K Mixed 5/10 Entry $26.64 to $26.50 Now $25.54 −4.13% ▼ −0.53% −0.14% vs SPY
- Aug 12, 202613w ago Institutional Cluster Bullish 4/10 Entry $26.95 to $26.64 Now $25.54 −5.23% ▼ −1.15% −0.71% vs SPY
- Aug 4, 202614w ago 8-K Neutral 4/10 Entry $28.35 to $27.61 Now $25.54 −9.91% ▼ −2.61% −2.51% vs SPY
- Jul 30, 202615w ago 8-K Bullish 7/10 Entry $26.75 to $27.01 Now $25.54 −4.52% ▲ +0.97% −2.65% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 6/10 Entry $20.49 to $19.39 Now $25.54 −24.65% ▲ +5.37% +5.80% vs SPY
- May 8, 202627w ago 8-K Neutral 2/10 Entry $17.53 to $17.79 Now $25.54 +45.69% ▲ +1.48% +1.57% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers